Furthermore, metformin impacts on certain aspects of the SASP, particularly by reducing WTI-induced Ccl2 levels, which in turn impact on adjacent vascular structures resulting in vascular dysfunction, namely increased vascular permeability, inflammation, and extravasation of circulating tumor cells as already shown [13,14,15]. Here, CCL2 is linked to neoplasm.